This certification represents that Titan’s quality management system maintains standards that meet international requirements specific to medical device design and development.
Titan Medical Completes Survival Phase of GLP Chronic Procedures with its Single-Port Robotic Surgical System
The Company now intends to complete the full GLP studies report and required Summative Human Factors studies, followed by the full Human Factors Evaluation (“HFE”) report to facilitate filing of the Investigational Device Exemption (“IDE”) submission by the end of September.
Titan Medical Completes Preclinical Good Laboratory Practice Procedures With Its Single-Port Robotic Surgical System
The Company intends to announce the results of required follow-up to the chronic procedures by the end of August.
3/21/19: The Company closed the Offering on March 21, 2019 and issued 7,352,941 units (the “Units”) for gross proceeds of approximately US $25,000,000. Each Unit was issued at a price of US $3.40 per Unit (the “Offering Price”) and is comprised of one common share of the Company (a “Common Share”) and one warrant entitling the holder to purchase one Common Share at a price of US $4.00 until expiry on March 20, 2024.
1/14/19: This accomplishment highlights the completion of a new camera system along with the design enhancements of both the surgeon workstation & the patient cart.
1/3/19: This accomplishment highlights the completion of a new camera system along with the design enhancements of both the surgeon workstation and the patient cart, the two primary components of the system. The engineering confidence build reflects all significant improvements inspired by the Company’s preclinical experience.